Paediatric retinal dysfunction linked to high vigabatrin doses

Article

Paediatric retinal dysfunction may be linked to exposure to high daily doses of vigabatrin.

Paediatric retinal dysfunction may be linked to exposure to high daily doses of vigabatrin, reveals a study in the Journal of Paediatric Ophthalmology and Strabismus.

Dr Ulrika Kjellstrom and her team, Department of Ophthalmology, University of Lund, Sweden, investigated the full-field electroretinographies (ff-ERG) of 14 children who were administered vigabatrin.

Drug dosage parameters were compared in all participants, along with the ff-ERGs from healthy controls and were grouped according to age.

For the isolated rod response, combined rod-cone response and the 30 Hz flicker response there was reduced b-wave amplitudes. In 57% of the children who received vigabatrin there were significant changes in ff-ERG. The study showed no differences in cumulative doses or duration of medication.

The study suggests that careful follow-up should be performed for children who are administered vigabatrin, as high doses are linked to retinal dysfunction and photoreceptor damage.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.